NeuroOne Strengthens Leadership Team with Appointment of Emily Johns as General Counsel and Corporate Secretary

Rhea-AI Summary

NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) has appointed Emily Johns as General Counsel and Corporate Secretary. Johns, previously a partner at Honigman LLP, brings extensive experience in securities and corporate governance, having represented NeuroOne since 2017. CEO Dave Rosa highlighted that Johns' appointment would strengthen the management team while reducing legal costs. As part of her compensation, Johns received options to purchase 500,000 shares at $0.611 per share. Additionally, the company granted its new senior director of quality assurance and regulatory affairs options for 75,000 shares under the same terms, with 25% vesting after one year and the remainder in quarterly installments.

Positive

• Appointment of experienced legal counsel with deep company knowledge (represented NeuroOne since 2017)
• Expected reduction in overall legal costs through in-house counsel hire
• Strategic strengthening of management team with public company expertise

Negative

• Potential share dilution from stock option grants totaling 575,000 shares

EDEN PRAIRIE, Minn., June 03, 2025 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced it has strengthened its management team with the appointment of Emily Johns as General Counsel and Corporate Secretary.

Dave Rosa, President and CEO of NeuroOne said, “We are excited to welcome Emily to NeuroOne especially after working with her for almost a decade. Her legal acumen and experience navigating dynamic, fast-growing organizations will be invaluable as we continue to scale our business. Beyond strengthening the management team, we believe this will reduce overall legal costs making it a financially prudent hire.”

"I am thrilled to be joining the NeuroOne team at such an exciting time for the company," said Ms. Johns. "I look forward to contributing to NeuroOne's momentum and helping the company execute on its strategic growth initiatives and drive shareholder value."

Ms. Johns is an experienced public company lawyer who most recently served as a partner at Honigman LLP, where she represented many biotechnology companies in securities and corporate governance matters, including representing NeuroOne on all transactional work since 2017. Previously, she began her career at Sullivan & Cromwell LLP, where she represented public companies in securities offerings and merger transactions. She received her J.D. from UCLA School of Law and her bachelor's degree from the University of Michigan.

In connection with her appointment, Ms. Johns received an option to purchase 500,000 shares of the Company’s common stock. On the same date, the Company granted its new senior director of quality assurance and regulatory affairs an option to purchase 75,000 shares. The options have an exercise price of $0.611 per share, with 25% vesting on the first anniversary of the grant date, and the remainder vesting in equal quarterly installments thereafter. The Company approved these awards as material inducement to these employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

About NeuroOne

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) is developing and commercializing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders that may improve patient outcomes and reduce procedural costs. The Company may also pursue applications for other areas such as depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be a forward–looking statement that reflects NeuroOne’s current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward–looking statements by the words or phrases “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “forecasts,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue, “focused on,” “committed to” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward–looking statements may include statements regarding the Company’s ability to scale its business, the reduction of overall legal costs, and the Company’s ability to execute on its strategic growth initiatives and drive shareholder value. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including risks related to whether the Company will continue to maintain compliance with all Nasdaq continued listing requirements, risks that our strategic partnerships may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages or otherwise; risks that our technology will not perform as expected based on results of our pre-clinical and clinical trials; risks related to uncertainties associated with the Company’s capital requirements to achieve its business objectives and ability to raise additional funds: the risk that we may not be able to secure or retain coverage or adequate reimbursement for our technology; uncertainties inherent in the development process of our technology; risks related to changes in regulatory requirements or decisions of regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks relate to clinical trial patient enrollment and the results of clinical trials; that we may be unable to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described under the heading “Risk Factors” in our filings with the Securities and Exchange Commission. These forward–looking statements speak only as of the date of this press release and NeuroOne undertakes no obligation to revise or update any forward–looking statements for any reason, even if new information becomes available in the future.

IR Contact
MZ Group – MZ North America
NMTC@mzgroup.us

FAQ

Who is NeuroOne's new General Counsel and what is her background?

Emily Johns is NeuroOne's new General Counsel and Corporate Secretary. She was previously a partner at Honigman LLP and has represented NeuroOne since 2017. She began her career at Sullivan & Cromwell LLP and holds a J.D. from UCLA School of Law.

What stock options were granted to NMTC's new General Counsel?

Emily Johns received options to purchase 500,000 shares at $0.611 per share, with 25% vesting after one year and the remainder vesting in quarterly installments.

How will the new General Counsel appointment benefit NeuroOne (NMTC)?

The appointment is expected to strengthen the management team, reduce overall legal costs, and help execute strategic growth initiatives while driving shareholder value.

What is NeuroOne Medical Technologies (NMTC) company focus?

NeuroOne is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders.

When did Emily Johns start working with NeuroOne (NMTC)?

Emily Johns has been working with NeuroOne since 2017 as their representative while she was a partner at Honigman LLP.